| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a protected amino acid, H-D-Met-OMe.HCl does not have a defined pharmacological target. Its primary role is as a chemical intermediate in peptide synthesis. Upon deprotection, D-methionine may interact with D-amino acid oxidase, an enzyme that catalyzes the oxidative deamination of D-amino acids. D-methionine may also interact with methionine transporters and other amino acid transport systems. In biological systems, methionine plays a crucial role in protein synthesis, methylation reactions, and as a precursor for cysteine and taurine. However, the compound itself is not a drug but a research tool.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies have shown that amino acid derivatives like H-D-Met-OMe.HCl influence the release of anabolic hormones and affect the availability of fuel for cellular activity. Research on methionine derivatives has demonstrated their effects on cellular metabolism, methylation pathways, and antioxidant defense systems. Studies suggest that amino acid derivatives are regarded as advantageous synergistic food ingredients. The D-enantiomer is of particular interest for studying stereospecific effects on cellular processes and for developing D-amino acid-containing peptides with enhanced stability against proteases. |
| ln Vivo |
In vivo studies on D-amino acid derivatives are limited but of growing interest due to their unique biological properties. D-methionine has been studied for its potential to modulate oxidative stress and support cellular function. Research in rodent models has shown that methionine derivatives can influence growth performance and metabolic pathways. However, as a protected methyl ester, H-D-Met-OMe.HCl itself has limited published in vivo data. The compound is primarily used as a synthetic intermediate rather than a bioactive agent.
|
| Enzyme Assay |
In vitro enzyme assays for methionine derivatives typically involve measuring their interaction with enzymes such as methionine adenosyltransferase, which catalyzes the formation of S-adenosylmethionine. A standard protocol involves incubating the compound with the enzyme in appropriate buffer systems (e.g., 50 mM Tris-HCl, pH 8.0, containing ATP and Mg²⁺) at 37°C. The reaction products are analyzed using HPLC or LC-MS. For D-amino acid oxidase assays, the compound is incubated with the enzyme and the production of hydrogen peroxide is measured using a coupled assay with peroxidase and a chromogenic substrate.
|
| Cell Assay |
In vitro cellular assays for H-D-Met-OMe.HCl typically employ cell lines such as HepG2, SH-SY5Y, or primary neuronal cultures to evaluate its effects on cellular metabolism and oxidative stress. A common protocol involves seeding cells in 96-well plates at appropriate densities and incubating overnight at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound (typically 1-1000 µM) for 24-72 hours. Cell viability is assessed using MTT or resazurin assays. Oxidative stress markers, such as glutathione levels and reactive oxygen species, can be measured using fluorescent probes. Methylation capacity may be evaluated by measuring S-adenosylmethionine levels.
|
| Animal Protocol |
In vivo animal studies with methionine derivatives typically utilize rodent models such as Wistar rats or C57BL/6 mice. A standard protocol involves oral administration or intraperitoneal injection of the compound at doses ranging from 50-500 mg/kg body weight. Animals are maintained under standard laboratory conditions. Blood samples are collected at predetermined time points for pharmacokinetic analysis. Tissue samples may be harvested for analysis of methionine levels, methylation markers, and oxidative stress parameters. Behavioral studies may evaluate cognitive function or motor performance. The compound is typically administered as a solution in sterile saline or PBS.
|
| ADME/Pharmacokinetics |
H-D-Met-OMe.HCl (molecular weight 199.70 g/mol) is a small, polar molecule with favorable aqueous solubility. The methyl ester is susceptible to hydrolysis by esterases, releasing the free acid. The compound has a melting point of approximately 251°C (dec.). The hydrochloride salt form enhances stability and solubility. Following absorption, the compound undergoes ester hydrolysis and normal methionine metabolism, with excretion occurring via renal and biliary routes. The D-enantiomer is metabolized by D-amino acid oxidase and may exhibit different pharmacokinetic properties compared to the L-enantiomer.
|
| Toxicity/Toxicokinetics |
The hydrochloride salt of H-D-Met-OMe exhibits low toxicity, consistent with its nature as an amino acid derivative. Acute toxicity is expected to be low, with an oral LD₅₀ in rodents likely >2000 mg/kg based on similar compounds. The compound is not considered genotoxic or carcinogenic. Skin and eye contact may cause mild irritation. Inhalation of dust should be avoided. The compound is stable under normal storage conditions.
|
| References | |
| Additional Infomation |
4-Iodo-D-phenylalanine is the D-enantiomer of 4-iodophenylalanine and also the enantiomer of 4-iodo-L-phenylalanine.
H-D-Met-OMe.HCl is supplied as a white to off-white solid powder with ≥98% purity. The compound has a molecular formula of C₆H₁₄ClNO₂S. It should be stored as a powder at -20°C for up to 3 years, at 4°C for up to 2 years, and in solution at -80°C for 6 months or -20°C for 1 month. The compound requires protection from light during transportation and storage. It is for research use only and is not approved for human therapeutic applications. |
| Molecular Formula |
C9H10INO2
|
|---|---|
| Molecular Weight |
291.0857
|
| Exact Mass |
290.975
|
| CAS # |
62561-75-5
|
| PubChem CID |
2733279
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
366.8±32.0 °C at 760 mmHg
|
| Melting Point |
251ºC (dec.)(lit.)
|
| Flash Point |
175.6±25.1 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
2.14
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
179
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC(=CC=C1C[C@H](C(=O)O)N)I
|
| InChi Key |
PZNQZSRPDOEBMS-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m1/s1
|
| Chemical Name |
(2R)-2-amino-3-(4-iodophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4354 mL | 17.1768 mL | 34.3536 mL | |
| 5 mM | 0.6871 mL | 3.4354 mL | 6.8707 mL | |
| 10 mM | 0.3435 mL | 1.7177 mL | 3.4354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
